News

In June 2025, ‘cutting edge’ results of SLE research have been presented at the EULAR 2025 in Barcelona. In this whitepaper, we discuss novel therapeutic approaches including monoclonal antibodies with dual action such as ianalumab and chimeric antigen receptor T cells (CAR-T cells) such as resecabtagene autoleucel; both targeting B cell receptors or proteins involved in B cell activation with the aim to provide a deep B cell depletion. Whether these investigational therapies can achieve durable drug-free responses is currently evaluated in clinical trials in patients with moderately to severely active SLE with or without lupus nephritis.

Charité Research Organisation GmbH has long-standing experience in the conduct of early phase projects for new medicines to treat SLE.

We want to share our expertise in this Whitepaper.

Author and Contact:
Claudia Werner, MD, PhD
Charité Research Organisation GmbH
Charitéplatz 1, 10117 Berlin
claudia.werner@charite-research.org